TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03291353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg IV given every three weeks
Study: NCT01264731

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MELITAC 12.1
Description: Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants in cohort 1 will receive MELITAC 12.1 (100 mcg each of the12-MP and 200 mcg of Peptide-tet) administered subcutaneously (1 ml) and intradermally (1 ml) in Montanide ISA-51 VG adjuvant at a single vaccination site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: Topical Imiquimod regimen: Beginning on day 1, patients in cohorts 1 and 2 will have one or more cutaneous melanoma metastases treated topically with 5% imiquimod cream, with a dose of 1 to 3 packets of imiquimod daily, (depending on the extent of cutaneous metastases). Each packet contains 250 mg of cream and may be used for a surface area of up to 20 cm2. The number of lesions that are treated will be dependent on the availability and size of the lesions. In addition, if available, at least two lesions will be followed without treatment with the plan that they will be excised at week 3 (day 22) and week 6 (day 43), respectively, as controls. Imiquimod will be applied daily for seven days each week for 12 weeks. One course of treatment will be three weeks in duration, with evaluation by a clinician after every treatment course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: Topical Imiquimod regimen: Beginning on day 1, patients in cohorts 1 and 2 will have one or more cutaneous melanoma metastases treated topically with 5% imiquimod cream, with a dose of 1 to 3 packets of imiquimod daily, (depending on the extent of cutaneous metastases). Each packet contains 250 mg of cream and may be used for a surface area of up to 20 cm2. The number of lesions that are treated will be dependent on the availability and size of the lesions. In addition, if available, at least two lesions will be followed without treatment with the plan that they will be excised at week 3 (day 22) and week 6 (day 43), respectively, as controls. Imiquimod will be applied daily for seven days each week for 12 weeks. One course of treatment will be three weeks in duration, with evaluation by a clinician after every treatment course.
Study: NCT03906162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviews
Description: During the 12-week intervention, the participants will receive seven telephone calls from a physical therapist. The interviews will be held in week 1, 2,3,5,7,9, and 12.~The telephone call will consist of a motivational interview focused on enhancing the daily level of physical activity in the participants.~MI is a form of counselling aiming at prompting increases in self-efficacy, which may leave people more open to and invested in changing their behaviours and shows potential for significant effects for exercise behaviour change.~In addition to the telephone based motivational interviews, the experimental group will also receive the base intervention which is described in detail under the control intervention paragraph.
Study: NCT03457480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys about experience
Study: NCT00962754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physician no insight in the fluid balance chart
Description: physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
Study: NCT03185416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Training
Description: The intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
Study: NCT00753597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-medrone, Mabthera
Description: 125mg, 1gram, twice day 1 and day 15
Study: NCT05032417

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: implementation of evidence-based nutrition practice guidelines
Description: The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implementation of evidence-based nutrition practice guidelines
Description: The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
Study: NCT05367557

Intervention type: PROCEDURE
Intervention: laparoscopic cholecystectomy
Description: removal of the gallbladder by laparoscopy at pneumoperitoneum pressure setting of 12 or 8 mmHg

Intervention type: PROCEDURE
Intervention: laparoscopic cholecystectomy
Description: removal of the gallbladder by laparoscopy at pneumoperitoneum pressure setting of 12 or 8 mmHg
Study: NCT01271413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitively stimulating activities
Description: The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitively stimulating activities
Description: The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
Study: NCT00707460

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention (Macronutrient composition)
Description: The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.~All groups are exposed to nutrition education on serving size and portion size.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention (Macronutrient composition)
Description: The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.~All groups are exposed to nutrition education on serving size and portion size.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention (Macronutrient composition)
Description: The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.~All groups are exposed to nutrition education on serving size and portion size.
Study: NCT03256071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine plus Modified BUCY
Description: Decitabine:20 mg/m²/day on day -14 to -10;~Modified BUCY:~1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified BUCY
Description: 1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Study: NCT03900741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submerged healing
Description: Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a submerged healing protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-submerged healing
Description: Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a non-submerged healing protocol
Study: NCT00749268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AbsorbaTack
Description: Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProTack
Description: Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
Study: NCT01270230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bruthas Project
Description: The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard HIV Testing and Counseling
Description: This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
Study: NCT02739256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde voiding trial
Description: A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde voiding trial
Description: A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.
Study: NCT05060796

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells
Description: The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6/ kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
Study: NCT03492645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-and technology-facilitated treatment protocol
Description: 1. 8 video or telephone counseling sessions targeting PTSD symptoms related to smoking lapse. The first of these sessions will last approximately 45-60 minutes, and the remaining 7 sessions will last 20-30 minutes.~2. Use of the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed by our co-investigators at the National Center for PTSD to complement the IC protocol with evidence-based tools to support smoking cessation, such as motivational messaging and coping tools for managing PTSD symptoms associated with smoking lapse.~3. Use of the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor, compatible with iOS and Android smartphones, that provides CO readings to the user at any time in order to self-monitor progress in quitting. The Covita iCO mobile app is used with the iCO Smoerlyzer to display CO readings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Office-based treatment protocol
Description: Weekly face-to-face sessions using the unmodified treatment manual developed by McFall and Saxon, a protocol combining office-based therapy plus evidence-based pharmacotherapies for smoking cessation that doubled quit rates in veteran smokers with PTSD.
Study: NCT01867645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IgM-enriched Intravenous Immunoglobulins
Description: IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
Study: NCT02798874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
Study: NCT01867645

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human Albumin
Description: Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
Study: NCT02514772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP2013 - A Proposed biosimilar rituximab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Originator rituximab - Rituxan ® or MabThera ®
Study: NCT01223040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SYSTANE® Balance Lubricant Eye Drops
Description: Subjects will be dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
Study: NCT01639456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3-/CD19- natural killer cells
Description: Infused on Day 0. The final CD3-/CD19- product must contain at least 20% NK cells based on previous studies using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3-CD56+ natural killer cells
Description: Infused on Day 0. The final CD3-/CD56+ product must contain at least 70% NK cells based on a previous study using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® CD3 and CD19 Reagent System
Description: In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® CD3 and CD19 Reagent System
Description: In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® CD56 Reagent System
Description: CliniMACS® CD3 and CD19 Reagent System will be used in addition to CliniMACS® CD56 Reagent System to enrich CD56+ NK cells. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
Study: NCT03255798

Intervention type: DEVICE
Group type: OTHER
Intervention: G2 and G3
Description: Two iStent inject devices and one iStent supra device
Study: NCT01639456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Infused intravenously 60 mg/kg x day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Infused intravenously 60 mg/kg x day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 x days -6 through -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 x days -6 through -2
Study: NCT01014806

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: Trivalent Influenza Vaccine 15ug/strain, commercially licensed
Study: NCT01310530

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiotherapy
Description: Daily proton beam radiotherapy is delivered to the site of the breast tumor in ten treatment sessions over two week as an outpatient.
Study: NCT00626535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg Oral Once Daily
Study: NCT01639456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: IL-2 subcutaneously at 6 million units every other day for 6 doses - begin evening of the NK cell infusion.
Study: NCT00626535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Oral Once Daily
Study: NCT00153413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cookin' Up Health
Description: A brief nutrition intervention designed to improve dietary habits
Study: NCT03495726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace app
Description: Headspace is a Contemplative Application (App) for Well-being (CAW). Participants will be provided initial instructions for downloading and using the Headspace app. The Headspace app includes guided meditations, articles and videos. Participants will be asked to engage in meditation practice for an average of 10 minutes a day during the 6-week training period.
Study: NCT02948699

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrison
Description: Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
Study: NCT00903799

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of ENTERRA therapy
Description: Gastric electrical stimulation using Enterra Therapy
Study: NCT03396926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00574444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transvaginal diagnostic peritoneoscopy
Description: For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
Study: NCT00880880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-PAQ-PF
Description: Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
Study: NCT00014911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet Transplantation
Description: Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.